Natixis Advisors LLC Decreases Stake in Pfizer Inc. (NYSE:PFE)

Natixis Advisors LLC cut its position in Pfizer Inc. (NYSE:PFE) by 7.8% during the third quarter, HoldingsChannel reports. The firm owned 2,397,900 shares of the biopharmaceutical company’s stock after selling 203,516 shares during the quarter. Natixis Advisors LLC’s holdings in Pfizer were worth $69,395,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. China Universal Asset Management Co. Ltd. acquired a new position in Pfizer in the first quarter valued at $315,000. Jupiter Asset Management Ltd. acquired a new stake in shares of Pfizer in the 1st quarter valued at about $3,221,000. Edgestream Partners L.P. purchased a new position in Pfizer during the 1st quarter worth approximately $243,000. Hillsdale Investment Management Inc. increased its position in Pfizer by 111.3% during the first quarter. Hillsdale Investment Management Inc. now owns 3,132 shares of the biopharmaceutical company’s stock worth $87,000 after buying an additional 1,650 shares during the period. Finally, Resurgent Financial Advisors LLC boosted its holdings in shares of Pfizer by 16.6% in the first quarter. Resurgent Financial Advisors LLC now owns 36,270 shares of the biopharmaceutical company’s stock valued at $1,007,000 after acquiring an additional 5,173 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently commented on PFE. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. Wolfe Research assumed coverage on shares of Pfizer in a report on Friday. They issued an “underperform” rating and a $25.00 target price for the company. StockNews.com upgraded shares of Pfizer from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, November 12th. Citigroup began coverage on Pfizer in a research report on Friday, October 25th. They issued a “neutral” rating and a $30.00 price target on the stock. Finally, Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, five have given a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $32.92.

Insider Buying and Selling

In other news, Director Scott Gottlieb purchased 1,000 shares of the company’s stock in a transaction dated Wednesday, October 30th. The stock was acquired at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at $282,400. This represents a 11.11 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. 0.06% of the stock is currently owned by insiders.

Pfizer Price Performance

Pfizer stock opened at $24.80 on Friday. The company has a market cap of $140.54 billion, a P/E ratio of 33.51, a price-to-earnings-growth ratio of 0.79 and a beta of 0.67. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The business has a fifty day moving average of $28.64 and a two-hundred day moving average of $28.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. During the same quarter last year, the business earned ($0.17) earnings per share. The business’s revenue for the quarter was up 31.2% compared to the same quarter last year. As a group, analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 6.77%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s payout ratio is currently 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.